DEL VECCHIO, SILVANA
 Distribuzione geografica
Continente #
AS - Asia 5.354
NA - Nord America 4.501
EU - Europa 3.192
SA - Sud America 586
AF - Africa 170
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 13.812
Nazione #
US - Stati Uniti d'America 4.327
SG - Singapore 2.524
RU - Federazione Russa 1.473
VN - Vietnam 940
CN - Cina 930
IT - Italia 500
BR - Brasile 454
HK - Hong Kong 435
DE - Germania 204
FR - Francia 192
UA - Ucraina 164
FI - Finlandia 149
IE - Irlanda 121
BD - Bangladesh 95
CA - Canada 90
GB - Regno Unito 90
IN - India 82
SE - Svezia 80
JP - Giappone 74
NL - Olanda 65
AR - Argentina 56
BE - Belgio 52
MX - Messico 50
CI - Costa d'Avorio 49
KR - Corea 42
ZA - Sudafrica 36
PH - Filippine 30
IQ - Iraq 29
TH - Thailandia 24
PL - Polonia 22
AT - Austria 21
EC - Ecuador 21
TR - Turchia 17
MA - Marocco 16
ID - Indonesia 15
TW - Taiwan 15
VE - Venezuela 15
TN - Tunisia 14
CO - Colombia 11
LT - Lituania 11
ES - Italia 10
EG - Egitto 9
PY - Paraguay 9
SA - Arabia Saudita 9
UZ - Uzbekistan 9
DZ - Algeria 8
KZ - Kazakistan 8
PK - Pakistan 8
AE - Emirati Arabi Uniti 7
CL - Cile 7
DO - Repubblica Dominicana 7
HN - Honduras 7
JO - Giordania 6
NP - Nepal 6
PE - Perù 6
SN - Senegal 6
AZ - Azerbaigian 5
KE - Kenya 5
MY - Malesia 5
OM - Oman 5
BG - Bulgaria 4
CZ - Repubblica Ceca 4
GH - Ghana 4
IR - Iran 4
IS - Islanda 4
JM - Giamaica 4
AM - Armenia 3
AU - Australia 3
BO - Bolivia 3
CG - Congo 3
ET - Etiopia 3
GE - Georgia 3
IL - Israele 3
KG - Kirghizistan 3
LB - Libano 3
PA - Panama 3
QA - Qatar 3
RO - Romania 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AL - Albania 2
AO - Angola 2
BB - Barbados 2
BJ - Benin 2
BZ - Belize 2
DK - Danimarca 2
EU - Europa 2
HU - Ungheria 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
BA - Bosnia-Erzegovina 1
BW - Botswana 1
Totale 13.781
Città #
Singapore 1.171
San Jose 689
Hong Kong 422
Moscow 360
Chandler 322
Ashburn 288
Ho Chi Minh City 271
Beijing 224
Hanoi 204
Jacksonville 201
Santa Clara 163
The Dalles 142
Lauterbourg 138
Boston 129
Princeton 126
Naples 125
Millbury 124
Los Angeles 123
Woodbridge 107
Nanjing 88
Buffalo 71
Wilmington 69
Hefei 68
Tokyo 65
Amsterdam 53
New York 53
Da Nang 52
Houston 49
Haiphong 45
Brussels 42
Redondo Beach 41
Council Bluffs 40
Ottawa 40
Dallas 37
Munich 36
Des Moines 35
Seattle 35
Ann Arbor 34
Nanchang 34
São Paulo 34
Tianjin 33
Chicago 30
Orem 29
Napoli 28
Hebei 27
Shenyang 26
Nuremberg 25
Frankfurt am Main 24
Dublin 22
Milan 22
Lawrence 21
Changsha 20
Mexico City 20
Jiaxing 19
Brooklyn 18
Norwalk 18
Biên Hòa 17
Rome 17
San Francisco 17
Montreal 15
Seoul 15
Baghdad 14
Hải Dương 14
London 14
Toronto 14
Warsaw 14
Atlanta 13
Boardman 13
Kochi 13
Stockholm 13
Turku 13
Denver 12
Dong Ket 12
Falls Church 12
Chennai 10
Curitiba 10
Helsinki 10
Kronberg 10
Pune 10
Zhengzhou 10
Belo Horizonte 9
Falkenstein 9
Guayaquil 9
Phoenix 9
Poplar 9
Quận Bình Thạnh 9
Thái Bình 9
Can Tho 8
Guangzhou 8
Johannesburg 8
Kunming 8
Manchester 8
Mumbai 8
Rio de Janeiro 8
Washington 8
Charlotte 7
Columbus 7
Lappeenranta 7
Tashkent 7
Thái Nguyên 7
Totale 7.206
Nome #
2-deoxy-2[F-18] fluoro-D-GLUCOSE POSITRON EMISSION TOMOGRAPHY Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma 187
Heterogeneity of SSTR2 expression assessed by 68Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors 184
Tumor induced osteomalacia: a systematic review and individual patient's data analysis 175
Machine Learning and Texture Analysis of [18F]FDG PET/CT Images for the Prediction of Distant Metastases in Non-Small-Cell Lung Cancer Patients 170
Evaluation of metabolic response with 18F-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors. 156
Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study 152
Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma 152
Prediction of 2-[18F]FDG PET-CT SUVmax for Adrenal Mass Characterization: A CT Radiomics Feasibility Study 148
Heterogeneity of glycolytic phenotype determined by 18F-FDG PET/CT using coefficient of variation in patients with advanced non-small cell lung cancer 143
Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms 141
Investigation of integrin expression in cancer stem cells isolated from glioblastoma patients 140
ATM inhibition blocks glucose metabolism and amplifies the sensitivity of resistant lung cancer cell lines to oncogene driver inhibitors 137
Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors 136
2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis 135
Coefficient of variation in metastatic lymph nodes determined by 18F-FDG PET/CT in patients with advanced NSCLC: combination with coefficient of variation in primary tumors 132
Breast tumor cell invasion and pro-invasive activity of cancer-associated fibroblasts co-targeted by novel urokinase-derived decapeptides 132
Impact of COVID-19 pandemic on 2-[18F]FDG PET/CT imaging work-flow in a single medical institution: comparison among the three Italian waves 131
Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer 130
Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma 122
Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma 121
Epidermal growth factor (EGFR) and Transferrin (TRFR) receptor upregulation is induced by arabinoside cytosine (ARA-C) on human tumor cells. 120
Distribution of mediastinal lesions across multi-institutional, international, radiology databases 120
Metabolic tumor volume assessed by 18F-FDG-PET/CT for the prediction of outcome in patients with multiple myeloma 119
18F-FDG-PET/CT, 99mTc-MIBI and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study 119
Washout of 99mTc-Sestamibi in predicting response to chemotherapy in patients with multiple myeloma. 118
Oncologia 118
FDG-PET/CT imaging during the Covid-19 emergency: a southern Italian perspective 118
Functional imaging of multidrug resistance in breast cancer. 117
Performance of FDG-PET/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial 115
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer. 114
Non-canonical role of PDK1 as a negative regulator of apoptosis through macromolecular complexes assembly at the ER-mitochondria interface in oncogene-driven NSCLC 113
Neutrophil extracellular traps as an adhesion substrate for different tumor cells expressing RGD-binding integrins. 110
Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis. 110
Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells 110
Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma 109
Bone scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the jaw 108
99mTc-MIBI in the evaluation of breast cancer biology 107
Nuclear imaging in cancer theranostic 106
PET/CT in cancer research: from preclinical to clinical applications. 105
Permeabilità bronchiale transepiteliale. Basi funzionali ed implicazioni cliniche. 105
18F-FDG-PET/CT, 99mTc-MIBI and MRI in the evaluation of patients with multiple myeloma 102
F-18-FDG-PET/CT, 99mTC-MIBI and MRI in the evaluation of patients with multiple myeloma 102
Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy. 101
18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma 101
99mTc-MIBI uptake in Bcl-2 overexpressing non-Hodgkin's lymphoma patients during drug-induced apoptosis. 100
Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines. 99
Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcima 99
99mTc-MIBI in the evaluation of breast cancer biology 99
Combined imaging with 18F-FDG-PET/CT and 111In-labeled Octreotide SPECT for evaluation of thymic epithelial tumors 99
Brain metastases unresponsive to immunotherapy detected by 18F-FDG-PET/CT in a patient with melanoma 99
Tc99m-sestaMIBI uptake in nonsecretory multiple myeloma 97
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3. 97
La Medicina Nucleare in Oncologia 97
18F-FDG-PET/CT in the evaluation of bone marrow infiltration in patients with multiple myeloma. 96
99mTc-MIBI uptake in breast cancer cells during early phases of apoptosis induction with Staurosporine 95
Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients 93
Detection of leptomeningeal involvement by 18F-FDG-PET/CT in a patient with non-Hodgkin lymphoma 93
Nuclear Imaging of Apoptosis in Animal Tumor Models 91
Urokinase receptor interacts with avb5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer 91
Scintigraphic detection of multidrug resistance in cancer 91
European Association of Nuclear Medicine 91
What molecular imaging of cancer patients can teach us about COVID-19 90
Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells 90
Coefficient of variation and texture analysis of 18F-FDG PET/CT images for the prediction of outcome in patients with multiple myeloma 89
Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers 87
Radiolabeling approches for cholecystokinin B receptor imaging 87
Molecular imaging of tumor microenvironment: challenges and perspectives 87
SPECT imaging of endoplasmic reticulum-mediated tumor response to gefitinib and erlotinib in lung cancer 86
PET-based volumetric biomarkers for risk stratification of non-small cell lung cancer patients 86
Preclinical imaging in targeted cancer therapies. 85
In vitro receptor imaging for characterization of human solid tumors. 85
Detection of colon cancer with radiolabelled monoclonal antibodies. 84
Combined SPECT/CT and PET/CT for breast imaging 84
Vitronectin binding to urokinase receptor in human breast carcinoma 83
Mammoscintigrafia e carcinoma mammario 83
Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. 82
Metabolic Tumor Volume assessed by 18F-FDG-PET/CT in the evaluation of plasma cell mass and prediction of outcome in patients with multiple myeloma. 82
Technetium 99m sestamibi in multiple myeloma 81
99mTc-MIBI uptake is reduced in Bcl-2 overexpressing MCF-7 breast cancer cells 81
Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up 80
Evaluation of therapeutic response using iodine-131-B72.3 monoclonal antibody in patients with ovarian carcinoma. 80
111In-pentetreotide scintigraphy:procedure guidelines for tumor imaging 80
Annual Congress of the European Association of Nuclear Medicine Munich 2008 79
Scintimammography with 99mTc-MIBI versus dynamic MRI forn non-invasive characterization of breast masses 78
Fractional retention of 99mTc-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. 77
Coordinate modulation of glycolytic enzymes and OXPHOS by imatinib in BCR-ABL driven chronic myelogenous leukemia cells. 77
MIBI as prognostic factor in breast cancer 76
A new role for nuclear medicine in multiple myeloma. 76
Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography. 76
A reversible shift of driver dependence from EGFR to Notch1 in non-small cell lung cancer as a cause of resistance to tyrosine kinase inhibitors. 75
Use of 99mTc-sestamibi scintigraphy in multiple myeloma 74
Tumor clearance of Technetium 99m-Sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer 74
Avid (67)Ga uptake in multiple myeloma relapsing after bone marrow transplant. 74
Molecular imaging: High-resolution detectors for early diagnosis and therapy monitoring of breast cancer. 74
Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. 74
In vivo detection of multidrug-resistant (MDR1) phenotype by 99mTc-Sestamibi scan in untreated breast cancer patients. 73
Evaluation of the side effects of chemotherapy and radiotherapy on other organs 73
Imaging of αvβ3 expression by a bifunctional chimeric RGD peptide not cross-reacting with αvβ5. 73
Texture Analysis of 68Ga-DOTATOC PET/CT Images for the Prediction of Outcome in Patients with Neuroendocrine Tumors 72
Endobronchial administration of iodine-131 B72.3 monoclonal antibody in patients with lung cancer. 72
Totale 10.337
Categoria #
all - tutte 50.021
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.021


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022722 10 1 7 1 10 29 11 22 114 38 145 334
2022/2023769 162 57 14 64 95 88 4 71 122 48 38 6
2023/2024616 43 82 65 41 41 22 23 83 24 20 119 53
2024/20253.490 215 273 11 41 84 151 445 215 251 385 1.137 282
2025/20266.845 691 414 677 559 1.325 272 627 488 947 455 167 223
2026/202798 98 0 0 0 0 0 0 0 0 0 0 0
Totale 14.006